Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia

Blood

Volumn 96, Issue 10, 2000, Pages 3374-3380

  Mesa, R A ^a   Hanson, C A ^a   Rajkumar, S V ^a   Schroeder, G ^a   Tefferi, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETICULIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BONE MARROW; CANCER SURVIVAL; CELL AGGREGATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEGAKARYOCYTE; MULTIPLE MYELOMA; MYELOFIBROSIS; MYELOID METAPLASIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SPLEEN SIZE; THROMBOCYTHEMIA; TUMOR VASCULARIZATION;

EID: 0034670052     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.10.3374.h8003374_3374_3380     Document Type: Article

References (67)

1. Seminars in Medicine of the Beth Israel Hospital, Boston: Clinical applications of research on angiogenesis
2. Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis
3. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas
4. Tumor angiogenesis and micrometastasis in bone marrow of patients with early gastric cancer
5. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas
6. Breast carcinoma: Vascular density determined using CD105 antibody correlates with tumor prognosis
7. Independent prognostic importance of microvessel density in endometrial carcinoma
8. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
9. Evidence of increased angiogenesis in patients with acute myeloid leukemia
10. Angiogenesis in myelodysplastic syndromes
11. Increased angiogenesis in chronic myeloid leukemia and myelodysplastic syndromes [abstract]
12. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
13. Bone marrow angiogenesis has prognostic value in multiple myeloma: An Eastern Cooperative Oncology Group Study [abstract]
14. Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density (MVD) in bone marrow biopsies
15. Myelofibrosis with myeloid metaplasia
16. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders
17. Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system
18. Myelofibrosis with myeloid metaplasia in young individuals: Disease characteristics, prognostic factors and identification of risk groups
19. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survival
20. Splenectomy in myelofibrosis with myeloid metaplasia: A single-institutional experience with 223 patients
21. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia
22. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study
23. Effective treatment of myelofibrosis (MF) by autologous peripheral blood stem cell (PBSC) transplantation (PBSCT)
24. Idiopathic myelofibrosis: Pathogenesis, natural history and management
25. Agnogenic myeloid metaplasia: A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis
26. Elevated VEGP serum levels in idiopathic myelofibrosis [abstract]
27. Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera: An immunomorphometric study on trephine biopsies of the bone marrow
28. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis With Myeloid Metaplasia
29. Prognostic relevance of the endothelial marker CD 34 in ovarian cancer
30. Assessment of angiogenesis in breast carcinoma: An important factor in prognosis?
31. Comparison of different immunohistochemical methods in the assessment of angiogenesis: Lack of prognostic value in a group of 77 selected node-negative breast carcinomas
32. Computerized image analysis in the assessment of bone marrow angiogenesis in multiple myeloma
33. Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts
34. The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis
35. Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines: Potential role for interleukin-1 and TGF-beta
36. Regulation of human bone marrow-derived osteoprogenitor cells by osteogenic growth factors
37. Transforming growth factor-β regulates growth as well as collagen and fibronectin synthesis of human marrow fibrobiasts
38. Transforming growth factor-β and megakaryocytes in the pathogenesis of idiopathic myelofibrosis
39. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis
40. Hypoxia augments cytokine (transforming growth factor-beta (TGF-β) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts
41. TGF β-1 regulation of VEGF production by breast cancer cells
42. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor β-1
43. Human endothelial cell migration is stimulated by urokinase plasminogen activator:plasminogen activator inhibitor 1 complex released from endometrial stromal cells stimulated with transforming growth factor β1: Possible mechanism for paracrine stimulation of endometrial angiogenesis
44. Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: A mechanism associated with increased angiogenesis
45. Transforming growth factor-beta 1 inhibits generation of angiostatin by human pancreatic cancer cells
46. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1α
47. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor
48. Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase-dependent pathway
49. Vascular endothelial growth factor
50. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets
51. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
52. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma
53. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: Correlation with patient survival
54. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer
55. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma
56. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
57. Correlation of angiogenesis with disease activity in patients with acute myeloid leukemia [abstract]
58. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma
59. Prognostic factors in idiopathic (primary) osteomyelofibrosis
60. Primary myelofibrosis: A detailed statistical analysis of the clinicopathological variables influencing survival Ann Hematol
61. Splenic hematopoiesis in polycythemia vera: A morphologic and immunohistologic study
62. Extramedullary haemopoiesis in fetal and adult human spleen: A quantitative immunohistological study
63. Blood and spleen haematopoiesis in patients with myelofibrosis
64. Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: A concise update
65. Thalidomide is an inhibitor of angiogenesis
66. Antitumor activity of thalidomide in refractory multiple myeloma
67. Thalidomide anti-angiogenesis therapy (Rx) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF)